Allegra, Zyrtec Will Not Follow Claritin OTC In Near Future, Execs State
This article was originally published in The Tan Sheet
Executive Summary
Aventis and Pfizer have no plans to switch their low- and non-sedating antihistamines OTC in the wake of Schering-Plough's decision to pursue FDA approval of nonprescription Claritin, company execs said at the SG Cowen healthcare conference in Boston March 13